The Research and Development Activities of the Boehringer Ingelheim Corporation (BIC)
As a research and innovation-driven pharmaceutical group of companies, Boehringer Ingelheim is committed to the goal of discovering and developing products which represent high therapeutic value for patients, physicians and health care providers.
For a global player in the pharmaceutical industry it is no longer sufficient to develop drugs that simply match products already on the market. That is why we are constantly striving to develop new therapeutic solutions. Boehringer Ingelheim dedicates annually almost one fifth of net sales in its largest business segment, Prescription Medicines, to first-class research and development so that we can find new and better ways to improve health.
Our Global Research & Development Network
Research & Development at Boehringer Ingelheim is carried out at four research and development centres around the world, and three support centres in Europe the Americas and Asia. Research at each major centre has a distinct therapeutic focus.
The bridge between industry and academia is strengthened by the Research Institute of Molecular Pathology (IMP) in Vienna (Austria).
Our Research & Development Centres:
<>| Biberach and Ingelheim, Germany | Central Nervous System
Metabolism Respiratory |
| Ridgefield, Connecticut, USA | Cardiovascular Diseases
Immunology and Inflammation Non-Clinical Drug Development |
| Vienna, Austria | Research in Oncology
Research Institute of Molecular Pathology (IMP) |
| Laval, Quebec, Canada | Research in Virology |
Our Support Centres:
| Kobe, Japan |
Support for international drug discovery activities
Specific pharmacokinetic investigations |
| Milan, Italy | Support for synthesis in exploratory and lead optimization projects |
| Buenos Aires, Argentina | Support for drug formulation and manufacturing of medication for clinical trials |
